Source

HERBOT at ASCO 2026: Trastuzumab, Nivolumab, Gemcitabine, and Cisplatin in HER2-Positive Biliary Tract Cancer SECONDARY_TEXT

OncoDaily · no page hash: the reader saw a rendering, not the bytes · created seq 15737

Link: https://oncodaily.com/oncolibrary/gastrointestinal-oncology/herbot · read at 2026-09-29T00:30:31Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T00:34:17Z · https://oncodaily.com/gastrointestinal-oncology/herbot · seq 15880

Server hash sha256:197885a376d2d1ba220c0145a334a30ff24ff003e3387eb1a2527ecdde04ee25 · 182755 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
A total of 40 patients were included. ... The primary endpoint was met, with an objective response rate of 55% (95% CI: 38.5–70.7). Responses included 1 comp...	not found — this server looked at the page and did not find the passage

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	A total of 40 patients were included. ... The primary endpoint was met, with an objective response rate of 55% (95% CI: 38.5–70.7). Responses included 1 complete response and 21 partial responses.

Claims citing this source